Lutz Müller

4.6k total citations · 1 hit paper
67 papers, 2.2k citations indexed

About

Lutz Müller is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Lutz Müller has authored 67 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 18 papers in Cancer Research and 16 papers in Molecular Biology. Recurrent topics in Lutz Müller's work include Carcinogens and Genotoxicity Assessment (12 papers), Mesenchymal stem cell research (8 papers) and Hematopoietic Stem Cell Transplantation (7 papers). Lutz Müller is often cited by papers focused on Carcinogens and Genotoxicity Assessment (12 papers), Mesenchymal stem cell research (8 papers) and Hematopoietic Stem Cell Transplantation (7 papers). Lutz Müller collaborates with scholars based in Germany, Switzerland and United States. Lutz Müller's co-authors include Elmar Gocke, Delf Schmidt, Bodo Junge, W. Wingender, Ernst Truscheit, Werner Frommer, Thomas D. Pfister, Mirko Brandes, Carsten Müller‐Tidow and Heinrich Bürgin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lutz Müller

65 papers receiving 2.1k citations

Hit Papers

Chemistry and Biochemistry of Microbial α‐Glucosidase Inh... 1981 2026 1996 2011 1981 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lutz Müller Germany 23 920 491 451 440 307 67 2.2k
William R. Waud United States 30 1.6k 1.7× 606 1.2× 418 0.9× 186 0.4× 132 0.4× 81 2.8k
Ana Bela Sarmento‐Ribeiro Portugal 30 1.5k 1.7× 729 1.5× 140 0.3× 743 1.7× 62 0.2× 130 3.2k
Steven A. Akman United States 40 2.5k 2.7× 827 1.7× 229 0.5× 593 1.3× 41 0.1× 108 4.3k
Andrew M. Stern United States 32 1.6k 1.7× 644 1.3× 451 1.0× 359 0.8× 70 0.2× 89 3.3k
Raymond C. Bergan United States 43 2.4k 2.6× 1.4k 2.9× 189 0.4× 939 2.1× 103 0.3× 136 5.2k
Ana Cristina Gonçalves Portugal 27 1.2k 1.3× 588 1.2× 163 0.4× 568 1.3× 39 0.1× 132 2.7k
Sharon A. Glynn United States 36 1.6k 1.8× 850 1.7× 120 0.3× 971 2.2× 121 0.4× 76 4.0k
Yi‐Chang Liu Taiwan 24 615 0.7× 285 0.6× 321 0.7× 311 0.7× 96 0.3× 123 2.0k
Pascal Gauduchon France 37 1.7k 1.8× 642 1.3× 171 0.4× 999 2.3× 72 0.2× 107 3.2k
Gabi U. Dachs New Zealand 33 2.4k 2.6× 769 1.6× 125 0.3× 1.9k 4.4× 589 1.9× 85 4.5k

Countries citing papers authored by Lutz Müller

Since Specialization
Citations

This map shows the geographic impact of Lutz Müller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lutz Müller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lutz Müller more than expected).

Fields of papers citing papers by Lutz Müller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lutz Müller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lutz Müller. The network helps show where Lutz Müller may publish in the future.

Co-authorship network of co-authors of Lutz Müller

This figure shows the co-authorship network connecting the top 25 collaborators of Lutz Müller. A scholar is included among the top collaborators of Lutz Müller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lutz Müller. Lutz Müller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Müller, Lutz, et al.. (2025). Risdiplam: A Small Molecule mRNA Splice Modifier Approved to Treat SMA Disease. Toxicologic Pathology. 53(8). 695–699.
2.
Brummer, Christina, Daniel Wolff, Udo Holtick, et al.. (2022). High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group. Transplantation and Cellular Therapy. 28(6). 337.e1–337.e10. 14 indexed citations
3.
Pauli, Cornelius, Yi Liu, Christian Rohde, et al.. (2020). Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation. Blood. 135(23). 2059–2070. 59 indexed citations
4.
Bauer, Marcus, Lisa Paschold, Claudia Wickenhauser, et al.. (2020). Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma. PLoS ONE. 15(7). e0235786–e0235786. 2 indexed citations
5.
6.
7.
Guenther, Andreas, Birgit Jaber, Paul Jordan, et al.. (2018). A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. British Journal of Clinical Pharmacology. 85(1). 181–193. 74 indexed citations
8.
Wass, Maxi, et al.. (2016). Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia. PLoS ONE. 11(10). e0164587–e0164587. 24 indexed citations
9.
Guérard, Melanie, Andreas Zeller, Matthias Festag, et al.. (2014). Genotoxicity testing of peptides: Folate deprivation as a marker of exaggerated pharmacology. Toxicology and Applied Pharmacology. 279(3). 419–427. 7 indexed citations
10.
11.
Brandes, Mirko, et al.. (2011). Physical Responses of Different Small-Sided Game Formats in Elite Youth Soccer Players. The Journal of Strength and Conditioning Research. 26(5). 1353–1360. 76 indexed citations
12.
Dittmer, Angela, et al.. (2009). Human mesenchymal stem cells induce E-cadherin degradation in breast carcinoma spheroids by activating ADAM10. Cellular and Molecular Life Sciences. 66(18). 3053–3065. 56 indexed citations
13.
Müller, Lutz, Elmar Gocke, Thierry Lavé, & Thomas D. Pfister. (2009). Ethyl methanesulfonate toxicity in Viracept—A comprehensive human risk assessment based on threshold data for genotoxicity. Toxicology Letters. 190(3). 317–329. 66 indexed citations
14.
Gocke, Elmar, Lutz Müller, & Thomas D. Pfister. (2009). EMS in Viracept—Initial (‘traditional’) assessment of risk to patients based on linear dose response relations. Toxicology Letters. 190(3). 266–270. 11 indexed citations
15.
Pozniak, Anton, Lutz Müller, Miklos Salgo, et al.. (2009). Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept®, Roche): overview. AIDS Research and Therapy. 6(1). 18–18. 16 indexed citations
16.
Gocke, Elmar, Heinrich Bürgin, Lutz Müller, & Thomas D. Pfister. (2009). Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate. Toxicology Letters. 190(3). 254–265. 65 indexed citations
17.
Stock, Peggy, Martin S. Staege, Lutz Müller, et al.. (2008). Hepatocytes Derived From Adult Stem Cells. Transplantation Proceedings. 40(2). 620–623. 51 indexed citations
18.
Müller, Lutz, et al.. (1989). Mutagenicity testing of doxylamine succinate, an antinauseant drug. Toxicology Letters. 49(1). 79–86. 8 indexed citations
19.
Müller, Lutz, et al.. (1988). Short communication: Deletion 7q, trisomy 6 and 11 in a case of Merkel-cell carcinoma. Cancer Genetics and Cytogenetics. 33(2). 305–309. 30 indexed citations
20.
Müller, Lutz. (1988). Micronucleus induction in mouse and rat fetuses treated transplacentally during histogenesis with mitomycin c and 7,12‐dimethylbenz(a)anthracene. Teratogenesis Carcinogenesis and Mutagenesis. 8(5). 303–313. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026